Use of recombinant factor VIIa to control bleeding in an adolescent male with severe hemophilia A,HIV,thrombocytopenia,hepatitis C,and end-stage liver disease
Restricted accessResearch articleFirst published online July, 2002
Use of recombinant factor VIIa to control bleeding in an adolescent male with severe hemophilia A,HIV,thrombocytopenia,hepatitis C,and end-stage liver disease
Few options are available to treat hemorrhaging during the palliative care of patients. Blood products, such as plasma and platelets, are difficult to transfuse in the home or hospice setting. What is needed is a product that can be given in the home setting for effective control of hemorrhaging in patients with various types of coagulopathies. Unfortunately, no such product currently exists. One agent that may be beneficial in this clinical setting is recombinant factor VIIa. This factor was approved initially for controlling hemorrhaging in patients with hemophilia who have developed antibodies against factor VIII, known as inhibitors. It subsequently has been found to control bleeding in several other clinical situations. We will describe our use of this agent during the palliative care of a patient with numerous insults to his coagulation system.
Hedner U, Ingerslev J: Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci. 1998; 19(2): 163-176.
2.
Bajaj SP, Joist JH: New insights into how blood clots: Implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Semin Thromb Hemost. 1999; 25(4): 407-418.
3.
Monroe DM, Hoffman M, Allen G, et al.: The factor VII-platelet interplay: Effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost. 2000; 26(4): 373-377.
4.
Kristensen J, Killander A, et al.: Clinical experience with recombinant factor VII in patients with thrombocytopenia. Haemostasis. 1996; 26 (Suppl 1): 159-164.
5.
Vidarsson B, Onundarson PT: Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost. 2000; 83: 634-635.
6.
Plews DE, Thomas AE: Novel uses of recombinant factor VIIa. Blood. 1999; 94 (Suppl 1): 83b.
7.
Meijer K, Debraff W, et al.: Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa. Arch Intern Med. 2000; 160: 2216.
8.
Poon M, Demers C, et al.: Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999; 94: 3951-3953.
9.
Chuansumrit A, Sangkapreecha C, et al.: Successful epistaxix control in a patient with Glanzmann thrombasthenia by increased bolus injected dose of recombinant factor VIIa. Thromb Haemost. 1999; 82: 1778.
10.
Ancliff P, Leisen R: The use of recombinant factor VIIa in a patient with severe Glanzmann thrombasthenia to facilitate insertion of a port-a-cath. Blood Coag Fibrinolysis. 1999; 10: 447-448.
11.
Menart C, Trzecink MC, et al.: Continuous infusion of Novoseven during colectomy in a Glanzmann thrombasthenia patient with anti-glycoprotein IIb-IIIa antibodies. Haemophilia. 1998; 4: 299.
12.
Wielenga JJ, Siebel Y, et al.: Use of recombinant factor VIIa and HLA matched platelets to prevent bleeding during and after major surgery in a patient with Glanzmann’s thrombasthenia. Haemophilia. 1998; 4: 299.
13.
Tengborn LK, Petruson B: A patient with Glanzmann’s thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost. 1996; 65: 981-982.
14.
D’Orion R, Menart C, et al.: Use of recombinant factor VIIa in three patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost. 2000; 83: 644-647.
15.
Peters M, Heijboer H: Treatment of a patient with Bernard-Soulier syndrome and recurrent nose bleeds with recombinant factor VIIa. Thromb Haemost. 1998; 80: 352.
16.
Bernstein DE, Jeffers L, et al.: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology. 1997; 113: 1930-1937.
17.
Papathrodoridis GV, Chung S, et al.: Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepato-cellular cancer in liver cirrhosis. J Hepatology. 1999; 31: 747-750.
18.
Kalicinski P, Kaminski A: Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transpl Proc. 1999; 31: 378-379.
19.
Chuansumrit A, Cantaroganasir T, et al.: Recombinant active factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coag Fibrin. 2000; Suppl 1: S101-S105.
20.
Jeffers LE, Bernstein DE, et al.: The use of recombinant factor VIIa (rFVIIa) in laparoscopic liver biopsy. Gastroenterology. 1998; 114: L0275.
21.
Hendriks HG, Meier K, et al.: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study. Transplantation. 2001; 15: 402-405.
22.
Vlot JA, Ton E, et al.: Treatment of a severely bleeding patient without pre-existing coagulopathy with activated recombinant factor VII. Am J Med. 2000; 108: 421-422.
23.
Kenet G, Walden R, et al.: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999: 354(9193): 1879.
24.
Revesz T, Arets B, et al.: Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost. 1998: 80: 353.
25.
Ciavarella N, Schiavoni M, et al.: Use of recombinant factor VIIa (Novoseven) in the treatment of two patients with type III von Willebrand’s disease and an inhibitor against von Willebrand factor. Haemostasis. 1996; 26(Suppl 1): 150-154.
